No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SMTI Sanara MedTech
- 32.190
- +0.350+1.10%
Trading May 1 14:39 ET
277.57MMarket Cap-61903P/E (TTM)
32.190High31.500Low4.24KVolume32.000Open31.840Pre Close134.68KTurnover0.12%Turnover RatioLossP/E (Static)8.62MShares46.40152wk High6.19P/B111.20MFloat Cap26.06052wk Low--Dividend TTM3.45MShs Float53.850Historical High--Div YieldTTM2.17%Amplitude17.410Historical Low31.802Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
FORT WORTH, TX, April 29, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused
Express News | Sanara MedTech Entered Into $55M Non-Dilutive Term Loan Agreement With CRG Servicing To Support Growth Initiatives In 2024 And 2025
Express News | Sanara Medtech Inc. Announces $55 Million Debt Facility
Sanara MedTech Apppoints Jake Waldrop COO >SMTI
Sanara MedTech Apppoints Jake Waldrop COO >SMTI
Sanara MedTech: Waldrop's Appointment Effective April 15 >SMTI
Sanara MedTech: Waldrop's Appointment Effective April 15 >SMTI
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer
FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused
Comments
Sanara MedTech's balance sheet is strained due to liabilities and lack of profitability. Its use of debt is risky, given its negative EBIT and free cash flow. However, its top-line growth is viewed positively.
Sanara MedTech's high P/S ratio is justified by its strong forecasted revenue growth, according to investor sentiment.
Analysts anticipate breakeven for Sanara MedTech within a year, indicating bullish outlook. The prospects hinge on company's maintenance of robust 225% annual growth rate. The firm's low debt, majorly equity-funded, reduces investment risk.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg